Down-regulation of microRNA-9 leads to activation of IL-6/Jak/STAT3 pathway through directly targeting IL-6 in HeLa cell

Molecular Carcinogenesis

Volumn 55, Issue 5, 2016, Pages 732-742

  Zhang, Jiangbo ^a,b   Jia, Junqiao ^a   Zhao, Lijun ^c   Li, Xiaojun ^a   Xie, Qing ^d   Chen, Xiangmei ^a   Wang, Jianliu ^c   Lu, Fengmin ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Cervical adenocarcinoma; HeLa; Hypermethylation; Interleukin 6; Jak STAT3 signaling pathway; MicroRNA 9 1

Indexed keywords

INTERLEUKIN 6; JANUS KINASE; MICRORNA 9; STAT3 PROTEIN; 3' UNTRANSLATED REGION; IL6 PROTEIN, HUMAN; MICRORNA; MIRN92 MICRORNA, HUMAN; STAT3 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOINFORMATICS; CANCER INHIBITION; CANCER SURGERY; CONTROLLED STUDY; DOWN REGULATION; ECTOPIC EXPRESSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HELA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUCIFERASE ASSAY; MALIGNANT TRANSFORMATION; MIGRATION INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; RNA METHYLATION; SIGNAL TRANSDUCTION; UTERINE CERVIX CARCINOMA; WESTERN BLOTTING; 3' UNTRANSLATED REGION; ANIMAL; CANCER TRANSPLANTATION; CELL PROLIFERATION; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; UTERINE CERVIX TUMOR;

3' UNTRANSLATED REGIONS; ANIMALS; CELL PROLIFERATION; DNA METHYLATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; INTERLEUKIN-6; JANUS KINASES; MICE; MICRORNAS; NEOPLASM TRANSPLANTATION; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; UTERINE CERVICAL NEOPLASMS;

EID: 84926444363     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22317     Document Type: Article

References (47)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90.
2. Pisani P, Bray F, Parkin DM. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 2002; 97:72-81.
3. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55:244-265.
4. Ambros V. The functions of animal microRNAs. Nature 2004; 431:350-355.
5. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6:857-866.
6. Johnson CD, Esquela-Kerscher A, Stefani G, et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 2007; 67:7713-7722.
7. Hu X, Schwarz JK, Lewis JS Jr, et al. A microRNA expression signature for cervical cancer prognosis. Cancer Res 2010; 70:1441-1448.
8. Rao Q, Shen Q, Zhou H, Peng Y, Li J, Lin Z. Aberrant microRNA expression in human cervical carcinomas. Med Oncol 2012; 29:1242-1248.
9. Wang X, Tang S, Le SY, et al. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS ONE 2008; 3:e2557.
10. LiW SC, ChanL C, HuC Y, LaiC H, Hsu N, Lin WC. Identification of homologous microRNAs in 56 animal genomes. Genomics 2010; 96:1-9.
11. Nass D, Rosenwald S, Meiri E, et al. MiR-92b and miR-9/9* are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumors. Brain Pathol 2009; 19:375-383.
12. Tan X, Wang S, Yang B, et al. The CREB-miR-9 negative feedback minicircuitry coordinates the migration and proliferation of glioma cells. PLoS ONE 2012; 7:e49570.
13. Ma L, Young J, Prabhala H. MiR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010; 12:247-256.
14. Zhu L, Chen H, Zhou D. MicroRNA-9 up-regulation is involved in colorectal cancer metastasis via promoting cell motility. Med Oncol 2012; 29:1037-1043.
15. Wan HY, Guo LM, Liu T, Liu M, Li X, Tang H. Regulation of the transcription factor NF-kappaB1 by microRNA-9 in human gastric adenocarcinoma. Mol Cancer 2010; 9:16.
16. Guo LM, Pu Y, Han Z. et al. MicroRNA-9 inhibits ovarian cancer cell growth through regulation of NF-kappaB1. FEBS J 2009; 276:5537-5546.
17. Liu S, Kumar SM, Lu H, et al. MicroRNA-9 up-regulates E-cadherin through inhibition of NF-kappaB1-Snail1 pathway in melanoma. J Pathol 2012; 226:61-72.
18. Selcuklu SD, Donoghue MT, Rehmet K, et al. MicroRNA-9 inhibition of cell proliferation and identification of novel miR-9 targets by transcriptome profiling in breast cancer cells. J Biol Chem 2012; 287:29516-29528.
19. Lehmann U, Hasemeier B, Christgen M, et al. Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J Pathol 2008; 214:17-24.
20. Bandres E, Agirre X, Bitarte N, et al. Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer 2009; 125:2737-2743.
21. Hildebrandt MA, Gu J, Lin J, et al. Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma. Oncogene 2010; 29:5724-5728.
22. Hu X, Schwarz JK, Lewis JS Jr, et al. A microRNA expression signature for cervical cancer prognosis. Cancer Res 2010; 70:1441-1448.
23. Wilting SM, Snijders PJ, Verlaat W, et al. Altered microRNA expression associated with chromosomal changes contributes to cervical carcinogenesis. Oncogene 2013; 32:106-116.
24. Wang Y, Cheng J, Xu C, et al. Quantitative methylation analysis reveals gender and age differences in p16INK4a hypermethylation in hepatitis B virus-related hepatocellular carcinoma. Liver Int 2012; 32:420-428.
25. Xie Q, Chen X, Lu F, et al. Aberrant expression of microRNA 155 may accelerate cell proliferation by targeting sex-determining region Y box 6 in hepatocellular carcinoma. Cancer 2012; 118:2431-2442.
26. Chen Z, Huang C, Yang YL, et al. Inhibition of the STAT3 signaling pathway is involved in the antitumor activity of cepharanthine in SaOS2 cells. Acta Pharmacol Sin 2012; 33:101-108.
27. Zhang D, Sun M, Samols D, Kushner I. STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6. J Biol Chem 1996; 271:9503-9509.
28. Block KM, Hanke NT, Maine EA, Baker AF. IL-6 stimulates STAT3 and Pim-1 kinase in pancreatic cancer cell lines. Pancreas 2012; 41:773-781.
29. Rotkrua P, Akiyama Y, Hashimoto Y, Otsubo T, Yuasa Y. MiR-9 downregulates CDX2 expression in gastric cancer cells. Int J Cancer 2011; 129:2611-2620.
30. Tsai KW, Liao YL, Wu CW, et al. Aberrant hypermethylation of miR-9 genes in gastric cancer. Epigenetics 2011; 6:1189-1197.
31. Tan HX, Wang Q, Chen LZ, et al. MicroRNA-9 reduces cell invasion and E-cadherin secretion in SK-Hep-1 cell. Med Oncol 2010; 27:654-660.
32. Vazquez-Mena O, Medina-Martinez I, Juárez-Torres E, et al. Amplified genes may be overexpressed, unchanged, or downregulated in cervical cancer cell lines. PLoS ONE 2012; 7:e32667.
33. Narayan G, Murty VV. Integrative genomic approaches in cervical cancer: Implications for molecular pathogenesis. Future Oncol 2010; 6:1643-1652.
34. Ojesina AI, Lichtenstein L, Freeman SS, et al. Landscape of genomic alterations in cervical carcinomas. Nature 2014; 506:371-375.
35. Iglesias M, Plowman GD, Woodworth CD. Interleukin-6 and interleukin-6 soluble receptor regulate proliferation of normal, human papillomavirus-immortalized, and carcinoma-derived cervical cells in vitro. Am J Pathol 1995; 146:944-952.
36. Takano H, Harigaya K, Ishii G, et al. Interleukin-6 (IL-6) production in carcinoma of the cervix. Arch Gynecol Obstet 1996; 258:25-33.
37. Srivani R, Nagarajan B. A prognostic insight on in vivo expression of interleukin-6 in uterine cervical cancer. Int J Gynecol Cancer 2003; 13:331-339.
38. Shi TY, Zhu ML, He J, et al. Polymorphisms of the Interleukin 6 gene contribute to cervical cancer susceptibility in Eastern Chinese women. Hum Genet 2013; 132:301-312.
39. Wei LH, Kuo ML, Chen CA, et al. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 2003; 22:1517-1527.
40. Weirauch U, Beckmann N, Thomas M, et al. Functional role and therapeutic potential of the pim-1 kinase in colon carcinoma. Neoplasia 2013; 15:783-794.
41. Carbajo-Pescador S, Ordonez R, Benet M, et al. Inhibition of VEGF expression through blockade of Hif1alpha and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells. Br J Cancer 2013; 109:83-91.
42. Cibull TL, Jones TD, Li L, et al. Overexpression of Pim-1 during progression of prostatic adenocarcinoma. J Clin Pathol 2006; 59:285-288.
43. Chen Z, Han ZC. STAT3: A critical transcription activator in angiogenesis. Med Res Rev 2008; 28:185-200.
44. Murphy GA, Solski PA, Jillian SA, et al. Cellular functions of TC10, a Rho family GTPase: Regulation of morphology, signal transduction and cell growth. Oncogene 1999; 18:3831-3845.
45. Shimi T, Butin-Israeli V, Adam SA, et al. The role of nuclear lamin B1 in cell proliferation and senescence. Genes Dev 2011; 25:2579-2593.
46. Hayashi T, Ohtsuka M, Okamura D, et al. Cytoskeleton-associated protein 2 is a potential predictive marker for risk of early and extensive recurrence of hepatocellular carcinoma after operative resection. Surgery 2014; 155:114-123.
47. Mencia N, Selga E, Noe V, Ciudad CJ. Underexpression of miR-224 in methotrexate resistant human colon cancer cells. Biochem Pharmacol 2011; 82:1572-1582.